Cargando…
S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature
RATIONALE: Small cell carcinoma of the esophagus (SCCE) is an uncommon but lethal disease characterized by dismal prognosis. Only 10% of advanced SCCE patients survive longer than 1 year. Resection is a choice for limited-stage cases, whereas the optimal treatment regimen for primary SCCE is yet to...
Autores principales: | Zhang, Chu, Yu, Guang-Mao, Zhang, Miao, Wu, Wenbin, Gong, Long-Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220406/ https://www.ncbi.nlm.nih.gov/pubmed/32011517 http://dx.doi.org/10.1097/MD.0000000000018892 |
Ejemplares similares
-
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020) -
Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020) -
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study
por: Wang, Lei, et al.
Publicado: (2017) -
First-line albumin-bound paclitaxel/carboplatin plus apatinib in advanced pulmonary sarcomatoid carcinoma: A case series and review of the literature
por: Kong, Feng-Wei, et al.
Publicado: (2020) -
Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)